Taking Advantage of the New Purple Book Patent Requirements for Biologics
By EsqSocial Corporation 26/04/21
New federal legislation will take effect this year that will require a reference product sponsor to submit to the FDA a list of any patents identified to a biosimilar applicant during the patent dance. The FDA is required to list these patents in the Purple Book....
By: Morgan Lewis